<DOC>
	<DOCNO>NCT00704054</DOCNO>
	<brief_summary>Ridaforolimus ( Deforolimus , AP23573 , MK-8669 ) mTor inhibitor show promising activity adult variety solid malignancy , particularly sarcoma . To date , study evaluate appropriate dosing obtain pharmacokinetic data pediatric patient conduct . Sarcomas second common solid malignancy child young adult , patient recurrent refractory disease , new therapy need . This initial evaluation ridaforolimus help define appropriate dose toxicity evaluation , well establish first pharmacokinetic biologic correlative data pediatric patient treat ridaforolimus .</brief_summary>
	<brief_title>A Multi-Center Phase I Study Intravenous Deforolimus ( AP23573 , MK-8669 ) Administered QDX5 Every Other Week Pediatric Patients With Advanced Solid Tumors ( 8669-028 ) ( COMPLETED )</brief_title>
	<detailed_description />
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Male female age 1 &lt; 18 year time study entry dose escalation portion study Histologic diagnosis malignant lymphoma solid tumor , include tumor central nervous system progressed opinion investigator despite standard therapy effective standard therapy know Patients may measurable nonmeasurable disease define RECIST Patients brainstem glioma intrinsic pontine glioma need biopsy proof diagnosis , must documentation local institution agreement among attend oncologist and/or neurooncologist , radiologist , neurosurgeon/pediatric neurosurgeon diagnostic imaging study consistent diagnosis brainstem intrinsic pontine glioma Patients must fully recover acute toxic effect prior chemotherapy , immunotherapy , surgery radiotherapy prior enter study Performance Status : EGOG 02 patient age 16 old ; Karnofsky &gt; 40 % patient &gt; 10 year age ; Lansky Play Scale &gt; 40 child &lt; 10 year age Life expectancy great equal 12 week There limit number prior treatment regimen provide performance status , organ function , life expectancy meet study criteria No persistent toxicity previous therapy &gt; Grade 2 NCI CTCAE version 3 . For patient CNS tumor ONLY , baseline neurotoxicity due primary tumor involvement postoperative complication , Grade 3 neurotoxicity allow stable Normal organ marrow function For female childbearing potential , negative pregnancy test must document prior enrollment Patients enter study sexual partner childbearing potential must agree use effective form contraception Patients chemotherapy radiotherapy within three ( 3 ) week ( six week nitrosoureas mitomycin C ) prior enter study , recover adverse event due agent administer 4 week earlier Patients receive investigational agent use investigational device Patients leukemia Patients previously receive deforolimus rapamycin analog History allergic reaction ( opinion investigator ) attribute compound similar chemical biologic composition deforolimus excipients use administration Uncontrolled intercurrent illness Pregnant woman exclude study teratogenic abortifacient effect deforolimus know time Because patient immune deficiency increase risk lethal infection treat marrowsuppressive therapy , know HIVpositive patient exclude study possible pharmacokinetic interaction deforolimus Autologous allogeneic stem cell transplant &lt; 3 month prior enrollment ; evidence ongoing graft versus host disease ( GVHD ) , GVHD require immunosuppressive therapy . Patients prior stem cell transplant regimens must discuss approve principal investigator prior registration</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>Pediatric</keyword>
	<keyword>Solid Tumor</keyword>
	<keyword>CNS Tumor</keyword>
	<keyword>Lymphoma</keyword>
</DOC>